AbbVie received approval from the U.S. FDA for SKYRIZI (risankizumab-rzaa) as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of moderately to severely active Crohn’s disease (CD). In two induction and one maintenance clinical trials, SKYRIZI demonstrated significant improvements in endoscopic response (defined as a decrease of greater than 50% from the baseline Simple Endoscopic Score in CD for patients with isolated ileal disease and, at least a 2-point red...